Nicotine and Nicotine Derivatives

Applications Sorbicillin analog. A bioactive secondary metabolites from terrestrial Streptomyces species TN262.
References Ma, L. et al. : J. Anitibiot. 64, 645 (2011); Elleuch, L. et al.: Appl. Biochem. Biotech. 162, 579 (2010)

Stability Hygroscopic, Light Sensitive
Applications (R,S)-Anatabine is a metabolite of Nicotine (N412420).
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Quan, P.M., et al.: J. Org. Chem., 30, 2769 (1965), Maciuk, A., et al.: J. Pharm. Biomed. Anal., 48, 238 (2008),

Stability Very Hygroscopic
Applications Nicotine N-β-D-Glucuronide is a Nicotine (N412420) metabolite in rat brain. Nicotine N-β-D-Glucuronide is used as a Nicotine biomarker in rat brain.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Alexandrov, K., et al.: Toxicol. Lett., 198, 63 (2010), Huang, L., et al.: J. Neurochem., 109, 826 (2009), Quik, M., et al.: Biochem. Pharmacol., 78, 677 (2009), Weems, J., et al.: Chem. Res. Toxicol., 23, 696 (2010),

Applications A metabolite of Nicotine.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Seeman, J.I. and Whidby, J.F.: J. Org. Chem., 41, 24, 3824 (1976), Oldendorf, W.H., et al.: Proc. Natl. Acad. Sci., USA, 90, 307 (1993)

Applications A labelled major metabolite of nicotine in humans. Carcinogen.
References Sugasawa, S., et al.: Pharma. Bull., et al.: 2, 39 (1954), Thompson, J.A., et al.: J. Chromatog., 231, 53 (1982); Seeman, J.I., et al.: J. Org. Chem., 51, 1548 (1986)

Applications 2-Chloro-rac-Nicotine is a metabolite of rac-Nicotine (N412420); an active stimulant having both addictive and carcinogenic properties.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Lowry, T., et al.: J. Chem. Soc., 319 (1931);

Stability Light Sensitive
Applications Labelled (RS)-Nornicotine (N757000). (RS)-Nornicotine is a tobacco alkaloid and the major Nicotine (N412420) metabolite in brain. Nornicotine appears to activate different nAChR subtypes, has a better pharmacokinetic profile, and produces less toxicity than Nicotine. Nornicotine shows a significant analgesic activity.
References Hecht, S., et al.: Carcinogenesis, 9, 875 (1988), Rivenson, A., et al.: Cancer Res., 48, 6912 (1988), Hoffmann, D., et al.: Chem. Res. Toxicol., 14, 767 (2001), Kool, J., et al.: J. Med. Chem., 49, 3287 (2006), Kool, J., et al.: Drug Metab. Dispos., 35, 640 (2007),

Applications Used in the preparation of 2-Aminodihydro[1,3]thiazines as BACE 2 inhibitors and their preparation and use in the treatment of diabetes.
References Denny, W., et al.: J. Med. Chem., 33, 814 (1990), Maurya, M., et al.: J. Chem. Res., 446 (1998),

Applications S)-(-)-Nicotine-d3 is an isotope labelled compound of (S)-(-)-Nicotine (N412450). (S)-(-)-Nicotine is a prototype nicotinic acetylcholine receptor agonist. (S)-(-)-Nicotine is a naturally occurring isomer. Nicotine can be absorbed through the alimentary canal, respiratory tract and intact skin. Nicotine is used in the treatment of smoking withdrawal syndrome. Nicotine has been used as an anthelmintic.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Geffken, D., et al.: Am. J. Epidemiol., 153, 242 (2001), Bolego, C., et al.: Cardiovasc. Res., 53, 568 (2002), Leone, A., et al.: Curr. Pharm. Des., 1, 2199 (2005),

Impurity Nicotine USP Related Compound F (3-(pyrrolidine-2-yl)pyridine)
Stability Light Sensitive
Applications (RS)-Nornicotine is a tobacco alkaloid and the major Nicotine (N412420) metabolite in brain. Nornicotine appears to activate different nAChR subtypes, has a better pharmacokinetic profile, and produces less toxicity than Nicotine. Nornicotine shows a significant analgesic activity. Nicotine USP Related Compound F (3-(pyrrolidine-2-yl)pyridine).
References Hecht, S., et al.: Carcinogenesis, 9, 875 (1988), Rivenson, A., et al.: Cancer Res., 48, 6912 (1988), Hoffmann, D., et al.: Chem. Res. Toxicol., 14, 767 (2001), Kool, J., et al.: J. Med. Chem., 49, 3287 (2006), Kool, J., et al.: Drug Metab. Dispos., 35, 640 (2007),